Rocket
Premium
Excel Add-In
International
Tools
Dashboard
Screener
Spinoffs
IPOs
Register
Alerts
Sign In
News + Filings
Key Docs
Charts
Ownership
Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
CC transcript
AMARIN CORP PLC (AMRN)
Create:
Alert
All
|
News
|
Filings
Date Filed
Type
Description
04/29/2021
GN
Amarin Reports First Quarter 2021 Financial Results and Provides Business Update
04/29/2021
GN
Amarin Announces Planned Retirement of Joseph T. Kennedy, EVP, General Counsel
04/22/2021
GN
Amarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines and Healthcare Products Regulatory Agency (MHRA) 1,2
04/20/2021
GN
Amarin to Report First Quarter Results and Host Conference Call on April 29, 2021
04/17/2021
GN
VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New Analyses of EVAPORATE Study Presented as Late-Breaking Science at ESC Preventive Cardiology 2021
04/06/2021
GN
Amarin Commences Commercial Initiatives for VAZKEPA in European Union Following Recent Regulatory Approval for Cardiovascular Risk Reduction Indication
03/17/2021
GN
VASCEPA® (Icosapent Ethyl) Found in Prespecified and Post Hoc Analyses to Significantly Reduce Stroke in At-Risk Patients in Analyses of Landmark REDUCE-IT® Study Presented at International Stroke Conference 2021
02/25/2021
GN
Amarin Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
02/18/2021
GN
Amarin to Present at Two Upcoming Investor Conferences
02/17/2021
GN
Amarin to Report Fourth Quarter and Full Year 2020 Results and Host Conference Call on February 25, 2021
02/16/2021
SC 13G/A
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2021
GN
Amarin Provides Update on VASCEPA® (Icosapent Ethyl) Regulatory Review Processes in Mainland China and Hong Kong
01/29/2021
GN
Amarin Receives Positive CHMP Opinion for Icosapent Ethyl for Cardiovascular Risk Reduction
01/25/2021
GN
Amarin Expands Cardiovascular Risk Reduction Patent Infringement Lawsuit to Include Health Care Insurance Provider
01/21/2021
GN
Icosapent Ethyl Included in the Chinese Society of Cardiology (CSC) Updated Guidelines for Primary Prevention of Cardiovascular Diseases
01/07/2021
GN
Amarin Provides Preliminary 2020 Results and 2021 Outlook
01/04/2021
GN
Amarin to Present at 39th Annual J.P. Morgan Healthcare Conference
12/14/2020
GN
Amarin Highlights Multiple VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at National Lipid Association (NLA) Scientific Sessions 2020, Including First COVID-19 Clinical Results
12/12/2020
GN
Amarin Reports Encouraging Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with VASCEPA® (Icosapent Ethyl) in Late Breaker Presentation at National Lipid Association (NLA) Scientific Sessions 2020
12/07/2020
GN
VASCEPA® (Icosapent Ethyl)-Related Scientific Findings to Be Presented at National Lipid Association (NLA) Scientific Sessions 2020
11/30/2020
GN
Amarin Files Patent Infringement Lawsuit Against Hikma
11/24/2020
GN
Amarin to Present at Piper Sandler's 32nd Annual Healthcare Conference (Virtual)
11/19/2020
GN
Amarin Shares Topline Data from Partner's Pivotal Phase 3 Study of VASCEPA® (Icosapent Ethyl) in Mainland China
11/13/2020
GN
VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Coronary Artery Bypass Grafting (CABG) Procedures in Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at American Heart Association's Virtual Scientific Sessions 2020
11/11/2020
GN
Amarin to Present at the Stifel 2020 Virtual Healthcare and Jefferies Virtual London Healthcare Conferences
11/05/2020
GN
Amarin Reports Third Quarter 2020 Financial Results and Provides Business Update
10/26/2020
GN
VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Cardiovascular Events in Patients with Compromised Renal Function at Baseline in Prespecified and Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at American Society of Nephrology (ASN) Kidney Week 2020
10/23/2020
GN
U.S. Veterans with Decreased Renal Function Shown to Be at Higher Risk for Adverse Cardiovascular Events if They Have Moderately Elevated Triglyceride (TG) Levels Despite Well-Controlled Low-Density Lipoprotein (LDL)-Cholesterol
10/19/2020
GN
Amarin to Report Third Quarter 2020 Results and Host Conference Call on November 5, 2020
10/15/2020
GN
VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Percutaneous Coronary Intervention (PCI) in Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at Transcatheter Cardiovascular Therapeutics (TCT) Connect 2020
10/05/2020
GN
Latest Research Evaluating VASCEPA® (Icosapent Ethyl) Mechanisms of Action Presented at European Atherosclerosis Society (EAS) Congress 2020
09/03/2020
GN
Amarin Provides Update Following Ruling in VASCEPA® ANDA Patent Litigation
09/01/2020
GN
Amarin Supports Latest Clinical Research Evaluating VASCEPA® (Icosapent Ethyl) in Patients with Persistent Cardiovascular Risk Presented at ESC Congress 2020, the Annual Meeting of the European Society of Cardiology
08/29/2020
GN
VASCEPA® (Icosapent Ethyl) Reported to Significantly Reduce Coronary Plaque in EVAPORATE Study Final Results Presented at ESC Congress 2020
Next >>
Rocket Data Systems, Inc. © 2019 |
Contact Us
|
Data Disclaimer
|
Terms of Use
|
Privacy